Smartlab Europe

Visiongain predicts boom in pharma contract manufacturing market

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
- Advertisement -

The global contract manufacturing will reach $64.07bn in 2016, according to a new report by London-based business information company Visiongain. The report, ‘Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021,’ says that the market will grow with a CAGR of 8.7% between 2010 and 2016, with finished dosage forms manufacturing driving the revenue growth. API manufacturing remained the largest market sector in 2010, accounting for 71.1% of the total market and the API manufacturers in India and China will achieve increasing demand for their services.Between 2011 and 2021, demand for contract manufacturing services will continue to come from developed market-based pharmaceutical companies, the Visiongain report says.

This decade, pharmaceutical companies will outsource increasing amounts of manufacturing, as companies focus on activities such as R&D and marketing. Growth in the biotechnology market will also provide a great opportunity for contract manufacturing organisations.

Latest stories

Related stories

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »